IVERIC bio, Inc. operates as a biopharmaceutical company. The company is headquartered in Parsippany, New Jersey and currently employs 74 full-time employees. The company went IPO on 2013-09-25. The firm is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).

Industry: Pharmaceutical Preparations Peers: Arcus Biosciences Inc EQRx, Inc. Immunitybio Inc Krystal Biotech Inc Lyell Immunopharma Inc Revolution Medicines Inc Recursion Pharmaceuticals Inc Twist Bioscience Corp Verve Therapeutics, Inc.